Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
prostate cancer
Pharma
Pfizer eyes earlier Talzenna use after ph. 3 prostate cancer win
If approved, Talzenna would be the first PARP inhibitor to enter the HRR-mutant metastatic hormone-sensitive prostate cancer setting.
Angus Liu
Mar 19, 2026 6:45am
Fierce Biotech
FDA to end 9-month adcomm hiatus with review of AZ cancer drugs
Mar 6, 2026 11:16am
Bayer sues J&J over 'deeply flawed' Erleada promotional claims
Feb 23, 2026 1:03pm
Bayer has Tony Romo calling plays in Nubeqa drive
Jan 29, 2026 10:40am
Novartis Super Bowl ad drafts NFL stars for prostate cancer push
Jan 29, 2026 9:30am
J&J PARP combo Akeega nabs new FDA nod in prostate cancer niche
Dec 15, 2025 12:14pm
